



## Clinical trial results:

### A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SUN13837 Injection in Adult Subjects with Acute Spinal Cord Injury

#### Summary

EudraCT number	2012-004373-80
Trial protocol	GB CZ ES PL
Global end of trial date	21 March 2015

#### Results information

Result version number	v1 (current)
This version publication date	31 July 2016
First version publication date	31 July 2016

#### Trial information

##### Trial identification

Sponsor protocol code	ASBI603
-----------------------	---------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01502631
WHO universal trial number (UTN)	-
Other trial identifiers	IND Number: 105,377

Notes:

##### Sponsors

Sponsor organisation name	Daiichi Sankyo, Inc
Sponsor organisation address	399 Thornall St., Edison, New Jersey, United States, 08837
Public contact	Clinical Trials Information, Asubio Pharmaceuticals, Inc., +001 201368 5020, info@asubio.com
Scientific contact	Clinical Trials Information, Asubio Pharmaceuticals, Inc., +001 201368 5020, info@asubio.com

Notes:

##### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	21 March 2015
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	21 March 2015
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The main objective of this study was to determine if treatment of acute spinal cord injury (ASCI) with SUN13837, when compared with placebo, resulted in a greater improvement in measures of overall functional independence by a comparison of the difference in the final mean total Spinal Cord Independence Measure, version III (SCIM III) scores between the 2 treatment groups.

Protection of trial subjects:

The safety assessments included adverse events, vital signs, electrocardiograms (ECGs), physical examination and clinical laboratory tests.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	08 July 2012
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Spain: 1
Country: Number of subjects enrolled	United Kingdom: 3
Country: Number of subjects enrolled	Czech Republic: 1
Country: Number of subjects enrolled	France: 3
Country: Number of subjects enrolled	United States: 53
Worldwide total number of subjects	61
EEA total number of subjects	8

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0

Adolescents (12-17 years)	0
Adults (18-64 years)	57
From 65 to 84 years	4
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

A total of 69 subjects screened. Of which 65 subjects were randomized. 4 subjects were randomized but not treated.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	SUN13837

Arm description:

Subjects received SUN13837 1 milligram per kilogram (mg/kg) intravenous injection once daily for 28 days.

Arm type	Experimental
Investigational medicinal product name	SUN13837
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received SUN13837 1 milligram per kilogram (mg/kg) intravenous injection once daily for 28 days.

<b>Arm title</b>	Placebo
------------------	---------

Arm description:

Subjects received placebo intravenous injection once daily for 28 days.

Arm type	Experimental
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received placebo intravenous injection once daily for 28 days.

<b>Number of subjects in period 1</b>	SUN13837	Placebo
Started	30	31
Completed	16	18
Not completed	14	13
Adverse event, serious fatal	2	3
Early withdrawal from study treatment	6	5
Consent withdrawn by subject	-	1
Subject Non-Compliant	1	-
Unspecified	3	2
Lost to follow-up	2	2

## Baseline characteristics

### Reporting groups

Reporting group title	SUN13837
-----------------------	----------

Reporting group description:

Subjects received SUN13837 1 milligram per kilogram (mg/kg) intravenous injection once daily for 28 days.

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Subjects received placebo intravenous injection once daily for 28 days.

Reporting group values	SUN13837	Placebo	Total
Number of subjects	30	31	61
Age categorical Units: Subjects			
Adults (18-64 years)	28	29	57
From 65-84 years	2	2	4
Age continuous Units: years			
arithmetic mean	37.9	38.8	
standard deviation	± 16.58	± 17.22	-
Gender categorical Units: Subjects			
Female	4	5	9
Male	26	26	52

## End points

### End points reporting groups

Reporting group title	SUN13837
Reporting group description:	
Subjects received SUN13837 1 milligram per kilogram (mg/kg) intravenous injection once daily for 28 days.	
Reporting group title	Placebo
Reporting group description:	
Subjects received placebo intravenous injection once daily for 28 days.	

### Primary: Spinal Cord Independence Measure, version III (SCIM III) Total Score at Week 16

End point title	Spinal Cord Independence Measure, version III (SCIM III) Total Score at Week 16
End point description:	
The SCIM III is a comprehensive rating scale that measures the ability of subjects with spinal cord injury to perform everyday tasks. The SCIM III has 19 items that assess 3 domains: Self-Care (6 items, scores range from 0 to 20), Respiration and Sphincter Management (4 items, scores range from 0 to 40), and Mobility (9 items, scores range from 0 to 40). The total SCIM score ranges from 0 to 100. Higher value represents increase in the improvement. The Intent-to-Treat population included all randomized subjects who received at least 7 doses of study drug and had at least 1 SCIM III evaluation.	
End point type	Primary
End point timeframe:	
Week 16	

End point values	SUN13837	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	27	28		
Units: units on a scale				
least squares mean (standard error)	38.14 ( $\pm$ 4.74)	33.6 ( $\pm$ 4.703)		

### Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	SUN13837 v Placebo
Number of subjects included in analysis	55
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4912
Method	ANCOVA
Parameter estimate	Least Square Mean
Point estimate	4.54

Confidence interval	
level	90 %
sides	2-sided
lower limit	-6.48
upper limit	15.56
Variability estimate	Standard error of the mean
Dispersion value	6.524

### Secondary: Total Motor Score (TMS) of International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) at Week 16

End point title	Total Motor Score (TMS) of International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) at Week 16
-----------------	---

End point description:

The TMS was the sum of the overall Upper Extremity Motor Score (UEMS) and the overall Lower Extremity Motor Score (LEMS) of ISNCSCI. The Upper Extremity Motor Score (UEMS) was defined as the sum of the motor function scores (based on the 0 to 5-point scale). A separate sum was obtained for the right and left sides (a maximum of 25 points each) and for an overall score (with a maximum score of 50). The Lower Extremity Motor Score (LEMS) was defined as the sum of the motor function scores. A separate sum was obtained for the right and left sides (a maximum of 25 points each) and for an overall score (with a maximum score of 50). Therefore, the maximum TMS score was 100. The TMS score reaches a maximum of 100 points in an individual with a fully functional spinal cord. The Intent-to-Treat population included all randomized subjects who received at least 7 doses of study drug and had at least 1 SCIM III evaluation.

End point type	Secondary
End point timeframe:	Week 16

End point values	SUN13837	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	27	28		
Units: units on a scale				
least squares mean (standard error)	16.58 (± 4.277)	14.07 (± 4.175)		

### Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Placebo v SUN13837
Number of subjects included in analysis	55
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6719
Method	ANCOVA
Parameter estimate	Least Square Mean
Point estimate	2.51

Confidence interval	
level	90 %
sides	2-sided
lower limit	-7.37
upper limit	12.38
Variability estimate	Standard error of the mean
Dispersion value	5.874

### Secondary: Self-Care and Mobility Subscale Scores of Spinal Cord Independence Measure, version III (SCIM III) at Week 16

End point title	Self-Care and Mobility Subscale Scores of Spinal Cord Independence Measure, version III (SCIM III) at Week 16
-----------------	---

End point description:

The SCIM III is a comprehensive rating scale that measures the ability of subjects with spinal cord injury to perform everyday tasks. The SCIM III has 19 items that assess 3 domains: Self-Care (6 items, scores range from 0 to 20), Respiration and Sphincter Management (4 items, scores range from 0 to 40), and Mobility (9 items, scores range from 0 to 40). The total SCIM score ranges from 0 to 100. SCIM III Self-Care subscale offered a means to evaluate upper extremity activities. Higher value represents increase in the improvement. The Intent-to-Treat population included all randomized subjects who received at least 7 doses of study drug and had at least 1 SCIM III evaluation.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 16

End point values	SUN13837	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	27	28		
Units: units on a scale				
least squares mean (standard error)	18.73 ( $\pm$ 3.124)	15.02 ( $\pm$ 3.101)		

### Statistical analyses

<b>Statistical analysis title</b>	Statistical Analysis 1
Comparison groups	SUN13837 v Placebo
Number of subjects included in analysis	55
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.3951
Method	ANCOVA
Parameter estimate	Least Square Mean
Point estimate	3.71

Confidence interval	
level	90 %
sides	2-sided
lower limit	-3.59
upper limit	11.01
Variability estimate	Standard error of the mean
Dispersion value	4.298

### Secondary: Number of Subjects With American Spinal Injury Association Impairment Scale (AIS) Grade - Improvement from Baseline at Final Assessment at Week 16

End point title	Number of Subjects With American Spinal Injury Association Impairment Scale (AIS) Grade - Improvement from Baseline at Final Assessment at Week 16
-----------------	--

End point description:

Subjects were assessed for AIS based on the following grading scheme: A (complete, no motor or sensory function is preserved in the sacral levels 4 through 5), B (incomplete, sensory but no motor function is preserved below the neurological level and includes sacral levels 4 through 5), C (incomplete, motor function is preserved below the neurological level and more than half of the key muscles below the neurological level have a muscle grade of less than 3), D (incomplete, motor function preserved below the neurological level and at least half of the key muscles below the neurological level have a muscle grade of 5 or more) and E (normal). Improvement was defined as 1 or more shift toward AIS grade (B-E) from baseline. The Intent-to-Treat population included all randomized subjects who received at least 7 doses of study drug and had at least 1 SCIM III evaluation. Here, "N" is number of subjects analyzed for this endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 16

End point values	SUN13837	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	27	27		
Units: subjects	12	15		

### Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	SUN13837 v Placebo
Number of subjects included in analysis	54
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4916
Method	ANCOVA
Parameter estimate	Odds ratio (OR)
Point estimate	0.67

---

Confidence interval

level	90 %
sides	2-sided
lower limit	0.26
upper limit	1.73

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

From First Administration of Study Drug up to End of Study (Day 182)

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	15.0
--------------------	------

### Reporting groups

Reporting group title	SUN13837
-----------------------	----------

Reporting group description:

Subjects received SUN13837 1 milligram per kilogram (mg/kg) intravenous injection once daily for 28 days.

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Subjects received placebo intravenous injection once daily for 28 days.

<b>Serious adverse events</b>	SUN13837	Placebo	
Total subjects affected by serious adverse events			
subjects affected / exposed	11 / 30 (36.67%)	17 / 31 (54.84%)	
number of deaths (all causes)	2	2	
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Multiple myeloma			
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	1 / 30 (3.33%)	1 / 31 (3.23%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypotension			
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Surgical and medical procedures			

Withdrawal of life support subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Euthanasia			
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Respiratory, thoracic and mediastinal disorders			
Respiratory failure			
subjects affected / exposed	3 / 30 (10.00%)	3 / 31 (9.68%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 1	0 / 0	
Pulmonary embolism			
subjects affected / exposed	3 / 30 (10.00%)	0 / 31 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleural effusion			
subjects affected / exposed	1 / 30 (3.33%)	1 / 31 (3.23%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute respiratory failure			
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypercapnia			

subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Hypoxia</b>			
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Pneumonia aspiration</b>			
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Respiratory distress</b>			
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Investigations</b>			
<b>Hepatic enzyme increased</b>			
subjects affected / exposed	2 / 30 (6.67%)	1 / 31 (3.23%)	
occurrences causally related to treatment / all	1 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Electrocardiogram QT prolonged</b>			
subjects affected / exposed	1 / 30 (3.33%)	1 / 31 (3.23%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Cardiac disorders</b>			
<b>Bradycardia</b>			
subjects affected / exposed	1 / 30 (3.33%)	2 / 31 (6.45%)	
occurrences causally related to treatment / all	0 / 1	1 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Cardiac arrest</b>			
subjects affected / exposed	1 / 30 (3.33%)	1 / 31 (3.23%)	
occurrences causally related to treatment / all	2 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Arrhythmia</b>			

subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Nervous system disorders</b>			
Convulsion			
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ischaemic stroke			
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Presyncope			
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Blood and lymphatic system disorders</b>			
Anaemia			
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Gastrointestinal disorders</b>			
Gastrointestinal haemorrhage			
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper gastrointestinal haemorrhage			
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Hepatobiliary disorders</b>			
Cholecystitis			

subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Skin and subcutaneous tissue disorders</b>			
Decubitus ulcer			
subjects affected / exposed	1 / 30 (3.33%)	1 / 31 (3.23%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Renal and urinary disorders</b>			
Renal failure acute			
subjects affected / exposed	1 / 30 (3.33%)	1 / 31 (3.23%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anuria			
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyuria			
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urine abnormality			
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Endocrine disorders</b>			
Thyroiditis			
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Infections and infestations</b>			
Urinary tract infection			

subjects affected / exposed	3 / 30 (10.00%)	3 / 31 (9.68%)	
occurrences causally related to treatment / all	0 / 3	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Pneumonia</b>			
subjects affected / exposed	3 / 30 (10.00%)	1 / 31 (3.23%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
<b>Escherichia urinary tract infection</b>			
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Lower respiratory tract infection</b>			
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Lung infection pseudomonal</b>			
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Pneumonia streptococcal</b>			
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Sepsis</b>			
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Urinary tract infection fungal</b>			
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 3 %

<b>Non-serious adverse events</b>	SUN13837	Placebo	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	30 / 30 (100.00%)	31 / 31 (100.00%)	
Vascular disorders			
Orthostatic hypotension			
subjects affected / exposed	9 / 30 (30.00%)	8 / 31 (25.81%)	
occurrences (all)	9	8	
Hypotension			
subjects affected / exposed	5 / 30 (16.67%)	6 / 31 (19.35%)	
occurrences (all)	5	6	
Deep vein thrombosis			
subjects affected / exposed	2 / 30 (6.67%)	5 / 31 (16.13%)	
occurrences (all)	2	5	
Hypertension			
subjects affected / exposed	1 / 30 (3.33%)	5 / 31 (16.13%)	
occurrences (all)	1	9	
Flushing			
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)	
occurrences (all)	1	0	
Neurogenic shock			
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)	
occurrences (all)	0	1	
Phlebitis			
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)	
occurrences (all)	3	0	
Phlebitis superficial			
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)	
occurrences (all)	0	1	
Thrombophlebitis superficial			
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)	
occurrences (all)	1	0	
Venous thrombosis limb			
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)	
occurrences (all)	2	0	

Surgical and medical procedures			
Osteosynthesis			
subjects affected / exposed	0 / 30 (0.00%)	2 / 31 (6.45%)	
occurrences (all)	0	2	
Sinus operation			
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)	
occurrences (all)	1	0	
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	17 / 30 (56.67%)	14 / 31 (45.16%)	
occurrences (all)	26	18	
Oedema peripheral			
subjects affected / exposed	5 / 30 (16.67%)	4 / 31 (12.90%)	
occurrences (all)	5	4	
Pain			
subjects affected / exposed	2 / 30 (6.67%)	2 / 31 (6.45%)	
occurrences (all)	2	2	
Chest pain			
subjects affected / exposed	1 / 30 (3.33%)	2 / 31 (6.45%)	
occurrences (all)	1	4	
Catheter site inflammation			
subjects affected / exposed	1 / 30 (3.33%)	1 / 31 (3.23%)	
occurrences (all)	1	1	
Generalised oedema			
subjects affected / exposed	1 / 30 (3.33%)	1 / 31 (3.23%)	
occurrences (all)	1	1	
Medical device pain			
subjects affected / exposed	0 / 30 (0.00%)	2 / 31 (6.45%)	
occurrences (all)	0	2	
Oedema			
subjects affected / exposed	0 / 30 (0.00%)	2 / 31 (6.45%)	
occurrences (all)	0	2	
Chest discomfort			
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)	
occurrences (all)	0	1	
Chills			

subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	1 / 31 (3.23%) 1	
Hyperthermia subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	1 / 31 (3.23%) 3	
Impaired healing subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	1 / 31 (3.23%) 1	
Implant site erosion subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	1 / 31 (3.23%) 1	
Influenza like illness subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	1 / 31 (3.23%) 1	
Irritability subjects affected / exposed occurrences (all)	1 / 30 (3.33%) 1	0 / 31 (0.00%) 0	
Temperature regulation disorder subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	1 / 31 (3.23%) 1	
Immune system disorders Drug hypersensitivity subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	1 / 31 (3.23%) 1	
Reproductive system and breast disorders Erectile dysfunction subjects affected / exposed occurrences (all)	2 / 30 (6.67%) 2	1 / 31 (3.23%) 1	
Penis disorder subjects affected / exposed occurrences (all)	2 / 30 (6.67%) 2	0 / 31 (0.00%) 0	
Cervix oedema subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	1 / 31 (3.23%) 1	
Epididymitis			

subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)	
occurrences (all)	0	1	
Genital burning sensation			
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)	
occurrences (all)	1	0	
Pelvic pain			
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)	
occurrences (all)	0	1	
Scrotal oedema			
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)	
occurrences (all)	0	1	
Vaginal discharge			
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)	
occurrences (all)	0	1	
Respiratory, thoracic and mediastinal disorders			
Nasal congestion			
subjects affected / exposed	8 / 30 (26.67%)	4 / 31 (12.90%)	
occurrences (all)	8	4	
Atelectasis			
subjects affected / exposed	5 / 30 (16.67%)	6 / 31 (19.35%)	
occurrences (all)	5	7	
Oropharyngeal pain			
subjects affected / exposed	5 / 30 (16.67%)	6 / 31 (19.35%)	
occurrences (all)	5	7	
Respiratory failure			
subjects affected / exposed	6 / 30 (20.00%)	4 / 31 (12.90%)	
occurrences (all)	6	6	
Pleural effusion			
subjects affected / exposed	6 / 30 (20.00%)	1 / 31 (3.23%)	
occurrences (all)	6	1	
Pneumonia aspiration			
subjects affected / exposed	3 / 30 (10.00%)	3 / 31 (9.68%)	
occurrences (all)	3	3	
Dyspnoea			

subjects affected / exposed	1 / 30 (3.33%)	4 / 31 (12.90%)
occurrences (all)	2	5
Increased bronchial secretion		
subjects affected / exposed	2 / 30 (6.67%)	2 / 31 (6.45%)
occurrences (all)	2	2
Pulmonary oedema		
subjects affected / exposed	2 / 30 (6.67%)	2 / 31 (6.45%)
occurrences (all)	2	2
Respiratory distress		
subjects affected / exposed	2 / 30 (6.67%)	2 / 31 (6.45%)
occurrences (all)	2	2
Cough		
subjects affected / exposed	1 / 30 (3.33%)	2 / 31 (6.45%)
occurrences (all)	1	2
Hypoxia		
subjects affected / exposed	2 / 30 (6.67%)	1 / 31 (3.23%)
occurrences (all)	2	1
Nasal dryness		
subjects affected / exposed	1 / 30 (3.33%)	2 / 31 (6.45%)
occurrences (all)	1	2
Aspiration		
subjects affected / exposed	0 / 30 (0.00%)	2 / 31 (6.45%)
occurrences (all)	0	2
Bronchial secretion retention		
subjects affected / exposed	0 / 30 (0.00%)	2 / 31 (6.45%)
occurrences (all)	0	2
Lung infiltration		
subjects affected / exposed	2 / 30 (6.67%)	0 / 31 (0.00%)
occurrences (all)	3	0
Tachypnoea		
subjects affected / exposed	1 / 30 (3.33%)	1 / 31 (3.23%)
occurrences (all)	1	1
Acute respiratory failure		
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)
occurrences (all)	0	1
Apnoea		

subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)
occurrences (all)	1	0
Bronchospasm		
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)
occurrences (all)	1	0
Choking		
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)
occurrences (all)	0	1
Diaphragmatic paralysis		
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)
occurrences (all)	0	1
Epistaxis		
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)
occurrences (all)	1	0
Haemoptysis		
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)
occurrences (all)	1	0
Hypoventilation		
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)
occurrences (all)	1	0
Pneumothorax		
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)
occurrences (all)	1	0
Pulmonary congestion		
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)
occurrences (all)	1	0
Pulmonary embolism		
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)
occurrences (all)	0	1
Respiratory acidosis		
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)
occurrences (all)	0	1
Respiratory depression		
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)
occurrences (all)	0	1
Respiratory depth decreased		

subjects affected / exposed occurrences (all)	1 / 30 (3.33%) 1	0 / 31 (0.00%) 0	
Sinus congestion subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	1 / 31 (3.23%) 1	
Tracheal oedema subjects affected / exposed occurrences (all)	1 / 30 (3.33%) 1	0 / 31 (0.00%) 0	
Wheezing subjects affected / exposed occurrences (all)	1 / 30 (3.33%) 1	0 / 31 (0.00%) 0	
Psychiatric disorders			
Insomnia subjects affected / exposed occurrences (all)	14 / 30 (46.67%) 17	12 / 31 (38.71%) 13	
Anxiety subjects affected / exposed occurrences (all)	9 / 30 (30.00%) 9	10 / 31 (32.26%) 13	
Depression subjects affected / exposed occurrences (all)	8 / 30 (26.67%) 9	9 / 31 (29.03%) 9	
Agitation subjects affected / exposed occurrences (all)	5 / 30 (16.67%) 5	1 / 31 (3.23%) 2	
Confusional state subjects affected / exposed occurrences (all)	2 / 30 (6.67%) 2	1 / 31 (3.23%) 1	
Delirium subjects affected / exposed occurrences (all)	1 / 30 (3.33%) 1	1 / 31 (3.23%) 1	
Adjustment disorder subjects affected / exposed occurrences (all)	1 / 30 (3.33%) 1	0 / 31 (0.00%) 0	
Alcohol withdrawal syndrome subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	1 / 31 (3.23%) 1	

Claustrophobia			
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)	
occurrences (all)	1	0	
Delirium tremens			
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)	
occurrences (all)	0	1	
Depressed mood			
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)	
occurrences (all)	1	0	
Hallucination			
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)	
occurrences (all)	1	0	
Mental status changes			
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)	
occurrences (all)	0	1	
Nightmare			
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)	
occurrences (all)	0	1	
Personality disorder			
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)	
occurrences (all)	0	1	
Psychotic disorder			
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)	
occurrences (all)	1	0	
Restlessness			
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)	
occurrences (all)	1	0	
Sleep disorder			
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)	
occurrences (all)	1	0	
Investigations			
Blood creatine phosphokinase increased			
subjects affected / exposed	7 / 30 (23.33%)	5 / 31 (16.13%)	
occurrences (all)	7	5	
Gamma-glutamyltransferase increased			

subjects affected / exposed	5 / 30 (16.67%)	3 / 31 (9.68%)
occurrences (all)	5	3
Blood lactate dehydrogenase increased		
subjects affected / exposed	3 / 30 (10.00%)	3 / 31 (9.68%)
occurrences (all)	5	4
Aspartate aminotransferase increased		
subjects affected / exposed	2 / 30 (6.67%)	3 / 31 (9.68%)
occurrences (all)	2	3
Alanine aminotransferase increased		
subjects affected / exposed	1 / 30 (3.33%)	3 / 31 (9.68%)
occurrences (all)	1	3
Haematocrit decreased		
subjects affected / exposed	4 / 30 (13.33%)	0 / 31 (0.00%)
occurrences (all)	4	0
Haemoglobin decreased		
subjects affected / exposed	4 / 30 (13.33%)	0 / 31 (0.00%)
occurrences (all)	4	0
Hepatic enzyme increased		
subjects affected / exposed	2 / 30 (6.67%)	2 / 31 (6.45%)
occurrences (all)	2	2
Blood alkaline phosphatase increased		
subjects affected / exposed	2 / 30 (6.67%)	1 / 31 (3.23%)
occurrences (all)	2	1
Platelet count decreased		
subjects affected / exposed	2 / 30 (6.67%)	1 / 31 (3.23%)
occurrences (all)	2	1
Blood creatine increased		
subjects affected / exposed	0 / 30 (0.00%)	2 / 31 (6.45%)
occurrences (all)	0	2
Blood glucose increased		
subjects affected / exposed	1 / 30 (3.33%)	1 / 31 (3.23%)
occurrences (all)	1	1
Body temperature increased		

subjects affected / exposed	2 / 30 (6.67%)	0 / 31 (0.00%)
occurrences (all)	2	0
Electrocardiogram QT prolonged		
subjects affected / exposed	1 / 30 (3.33%)	1 / 31 (3.23%)
occurrences (all)	1	1
International normalised ratio increased		
subjects affected / exposed	2 / 30 (6.67%)	0 / 31 (0.00%)
occurrences (all)	2	0
Neutrophil count increased		
subjects affected / exposed	2 / 30 (6.67%)	0 / 31 (0.00%)
occurrences (all)	4	0
Red blood cell count decreased		
subjects affected / exposed	2 / 30 (6.67%)	0 / 31 (0.00%)
occurrences (all)	2	0
White blood cell count increased		
subjects affected / exposed	2 / 30 (6.67%)	0 / 31 (0.00%)
occurrences (all)	2	0
Activated partial thromboplastin time prolonged		
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)
occurrences (all)	1	0
Bacterial test		
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)
occurrences (all)	1	0
Blood albumin decreased		
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)
occurrences (all)	1	0
Blood bicarbonate increased		
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)
occurrences (all)	1	0
Blood chloride decreased		
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)
occurrences (all)	1	0
Blood magnesium decreased		

subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)
occurrences (all)	1	0
Blood sodium decreased		
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)
occurrences (all)	0	1
Blood urea increased		
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)
occurrences (all)	1	0
Body temperature decreased		
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)
occurrences (all)	1	0
C-reactive protein increased		
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)
occurrences (all)	1	0
Chest X-ray abnormal		
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)
occurrences (all)	1	0
Electrocardiogram ST segment elevation		
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)
occurrences (all)	0	1
Electrocardiogram abnormal		
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)
occurrences (all)	1	0
Haemophilus test positive		
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)
occurrences (all)	1	0
Heart rate decreased		
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)
occurrences (all)	0	1
Mean arterial pressure decreased		
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)
occurrences (all)	0	1
Myelocyte count increased		
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)
occurrences (all)	1	0

Oxygen consumption increased subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	1 / 31 (3.23%) 1	
Oxygen saturation decreased subjects affected / exposed occurrences (all)	1 / 30 (3.33%) 1	0 / 31 (0.00%) 0	
Platelet count increased subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	1 / 31 (3.23%) 1	
Prothrombin time prolonged subjects affected / exposed occurrences (all)	1 / 30 (3.33%) 1	0 / 31 (0.00%) 0	
White blood cell count decreased subjects affected / exposed occurrences (all)	1 / 30 (3.33%) 1	0 / 31 (0.00%) 0	
White blood cells urine positive subjects affected / exposed occurrences (all)	1 / 30 (3.33%) 1	0 / 31 (0.00%) 0	
Injury, poisoning and procedural complications			
Excoriation subjects affected / exposed occurrences (all)	4 / 30 (13.33%) 6	2 / 31 (6.45%) 2	
Autonomic dysreflexia subjects affected / exposed occurrences (all)	2 / 30 (6.67%) 2	3 / 31 (9.68%) 3	
Procedural pain subjects affected / exposed occurrences (all)	3 / 30 (10.00%) 3	1 / 31 (3.23%) 1	
Procedural site reaction subjects affected / exposed occurrences (all)	1 / 30 (3.33%) 1	2 / 31 (6.45%) 2	
Muscle strain subjects affected / exposed occurrences (all)	2 / 30 (6.67%) 2	0 / 31 (0.00%) 0	
Post procedural haemorrhage			

subjects affected / exposed	1 / 30 (3.33%)	1 / 31 (3.23%)
occurrences (all)	2	1
Wound		
subjects affected / exposed	1 / 30 (3.33%)	1 / 31 (3.23%)
occurrences (all)	1	1
Clavicle fracture		
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)
occurrences (all)	1	0
Epicondylitis		
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)
occurrences (all)	0	1
Incision site oedema		
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)
occurrences (all)	1	0
Joint dislocation		
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)
occurrences (all)	1	0
Open wound		
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)
occurrences (all)	0	2
Penis injury		
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)
occurrences (all)	1	0
Pneumothorax traumatic		
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)
occurrences (all)	0	1
Post procedural oedema		
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)
occurrences (all)	1	0
Postoperative wound complication		
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)
occurrences (all)	0	1
Procedural haemorrhage		
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)
occurrences (all)	0	1
Pseudomeningocele		

subjects affected / exposed occurrences (all)	1 / 30 (3.33%) 1	0 / 31 (0.00%) 0	
Spinal column injury subjects affected / exposed occurrences (all)	1 / 30 (3.33%) 1	0 / 31 (0.00%) 0	
Wound dehiscence subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	1 / 31 (3.23%) 1	
Wound necrosis subjects affected / exposed occurrences (all)	1 / 30 (3.33%) 1	0 / 31 (0.00%) 0	
Cardiac disorders			
Bradycardia subjects affected / exposed occurrences (all)	5 / 30 (16.67%) 5	4 / 31 (12.90%) 5	
Tachycardia subjects affected / exposed occurrences (all)	8 / 30 (26.67%) 8	1 / 31 (3.23%) 1	
Atrial fibrillation subjects affected / exposed occurrences (all)	1 / 30 (3.33%) 1	1 / 31 (3.23%) 1	
Cardiac failure congestive subjects affected / exposed occurrences (all)	1 / 30 (3.33%) 1	0 / 31 (0.00%) 0	
Palpitations subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	1 / 31 (3.23%) 1	
Supraventricular extrasystoles subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	1 / 31 (3.23%) 1	
Supraventricular tachycardia subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	1 / 31 (3.23%) 1	
Ventricular extrasystoles subjects affected / exposed occurrences (all)	1 / 30 (3.33%) 1	0 / 31 (0.00%) 0	

Nervous system disorders			
Muscle spasticity			
subjects affected / exposed	12 / 30 (40.00%)	9 / 31 (29.03%)	
occurrences (all)	13	11	
Neuralgia			
subjects affected / exposed	13 / 30 (43.33%)	8 / 31 (25.81%)	
occurrences (all)	13	9	
Headache			
subjects affected / exposed	9 / 30 (30.00%)	4 / 31 (12.90%)	
occurrences (all)	10	5	
Dizziness			
subjects affected / exposed	3 / 30 (10.00%)	1 / 31 (3.23%)	
occurrences (all)	3	1	
Dysaesthesia			
subjects affected / exposed	3 / 30 (10.00%)	0 / 31 (0.00%)	
occurrences (all)	3	0	
Hypertonia			
subjects affected / exposed	1 / 30 (3.33%)	1 / 31 (3.23%)	
occurrences (all)	1	1	
Hypoaesthesia			
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)	
occurrences (all)	1	0	
Migraine			
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)	
occurrences (all)	0	1	
Paraesthesia			
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)	
occurrences (all)	1	0	
Sedation			
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)	
occurrences (all)	0	1	
Spinal cord compression			
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)	
occurrences (all)	0	1	
Spinal cord oedema			

subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)	
occurrences (all)	0	1	
Syncope			
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)	
occurrences (all)	1	0	
<b>Blood and lymphatic system disorders</b>			
Leukocytosis			
subjects affected / exposed	8 / 30 (26.67%)	10 / 31 (32.26%)	
occurrences (all)	8	13	
Anaemia			
subjects affected / exposed	5 / 30 (16.67%)	11 / 31 (35.48%)	
occurrences (all)	6	11	
Haemorrhagic anaemia			
subjects affected / exposed	2 / 30 (6.67%)	2 / 31 (6.45%)	
occurrences (all)	2	2	
Thrombocytopenia			
subjects affected / exposed	1 / 30 (3.33%)	2 / 31 (6.45%)	
occurrences (all)	1	2	
Thrombocytosis			
subjects affected / exposed	1 / 30 (3.33%)	1 / 31 (3.23%)	
occurrences (all)	1	1	
Bandaemia			
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)	
occurrences (all)	0	1	
Blood disorder			
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)	
occurrences (all)	0	2	
Eosinophilia			
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)	
occurrences (all)	1	0	
Normochromic normocytic anaemia			
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)	
occurrences (all)	0	1	
Nucleated red cells			
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)	
occurrences (all)	1	0	

<p>Ear and labyrinth disorders</p> <p>Cerumen impaction</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>2 / 30 (6.67%)</p> <p>2</p>	<p>0 / 31 (0.00%)</p> <p>0</p>	
<p>Ear pain</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 30 (0.00%)</p> <p>0</p>	<p>1 / 31 (3.23%)</p> <p>1</p>	
<p>Eye disorders</p> <p>Dry eye</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>5 / 30 (16.67%)</p> <p>5</p>	<p>3 / 31 (9.68%)</p> <p>3</p>	
<p>Diplopia</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 30 (3.33%)</p> <p>1</p>	<p>0 / 31 (0.00%)</p> <p>0</p>	
<p>Vision blurred</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 30 (3.33%)</p> <p>1</p>	<p>0 / 31 (0.00%)</p> <p>0</p>	
<p>Gastrointestinal disorders</p> <p>Nausea</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>12 / 30 (40.00%)</p> <p>15</p>	<p>10 / 31 (32.26%)</p> <p>14</p>	
<p>Constipation</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>7 / 30 (23.33%)</p> <p>12</p>	<p>11 / 31 (35.48%)</p> <p>17</p>	
<p>Diarrhoea</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>6 / 30 (20.00%)</p> <p>7</p>	<p>5 / 31 (16.13%)</p> <p>6</p>	
<p>Vomiting</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>5 / 30 (16.67%)</p> <p>7</p>	<p>6 / 31 (19.35%)</p> <p>6</p>	
<p>Dysphagia</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>5 / 30 (16.67%)</p> <p>5</p>	<p>5 / 31 (16.13%)</p> <p>6</p>	
<p>Ileus</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>6 / 30 (20.00%)</p> <p>6</p>	<p>4 / 31 (12.90%)</p> <p>4</p>	
<p>Neurogenic bowel</p>			

subjects affected / exposed	4 / 30 (13.33%)	4 / 31 (12.90%)
occurrences (all)	4	4
Haemorrhoids		
subjects affected / exposed	5 / 30 (16.67%)	2 / 31 (6.45%)
occurrences (all)	5	2
Dry mouth		
subjects affected / exposed	3 / 30 (10.00%)	2 / 31 (6.45%)
occurrences (all)	3	2
Dyspepsia		
subjects affected / exposed	2 / 30 (6.67%)	3 / 31 (9.68%)
occurrences (all)	2	5
Abdominal discomfort		
subjects affected / exposed	3 / 30 (10.00%)	1 / 31 (3.23%)
occurrences (all)	3	1
Abdominal distension		
subjects affected / exposed	0 / 30 (0.00%)	3 / 31 (9.68%)
occurrences (all)	0	3
Flatulence		
subjects affected / exposed	2 / 30 (6.67%)	1 / 31 (3.23%)
occurrences (all)	2	1
Abdominal pain		
subjects affected / exposed	2 / 30 (6.67%)	0 / 31 (0.00%)
occurrences (all)	2	0
Abdominal pain upper		
subjects affected / exposed	0 / 30 (0.00%)	2 / 31 (6.45%)
occurrences (all)	0	2
Gastrooesophageal reflux disease		
subjects affected / exposed	0 / 30 (0.00%)	2 / 31 (6.45%)
occurrences (all)	0	2
Haematochezia		
subjects affected / exposed	1 / 30 (3.33%)	1 / 31 (3.23%)
occurrences (all)	1	1
Oesophagitis		
subjects affected / exposed	1 / 30 (3.33%)	1 / 31 (3.23%)
occurrences (all)	1	1
Abdominal pain lower		

subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)
occurrences (all)	1	0
Anal ulcer		
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)
occurrences (all)	0	1
Anorectal discomfort		
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)
occurrences (all)	1	0
Dental caries		
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)
occurrences (all)	0	1
Duodenal ulcer		
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)
occurrences (all)	1	0
Eructation		
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)
occurrences (all)	0	1
Faeces discoloured		
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)
occurrences (all)	0	1
Frequent bowel movements		
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)
occurrences (all)	0	1
Gastritis		
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)
occurrences (all)	1	0
Haematemesis		
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)
occurrences (all)	1	0
Ileus paralytic		
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)
occurrences (all)	0	1
Impaired gastric emptying		
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)
occurrences (all)	0	1
Odynophagia		

subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	1 / 31 (3.23%) 1	
Proctalgia subjects affected / exposed occurrences (all)	1 / 30 (3.33%) 1	0 / 31 (0.00%) 0	
Reflux gastritis subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	1 / 31 (3.23%) 1	
Salivary hypersecretion subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	1 / 31 (3.23%) 1	
Toothache subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	1 / 31 (3.23%) 1	
<b>Skin and subcutaneous tissue disorders</b>			
Decubitus ulcer subjects affected / exposed occurrences (all)	13 / 30 (43.33%) 26	13 / 31 (41.94%) 24	
Rash subjects affected / exposed occurrences (all)	9 / 30 (30.00%) 10	4 / 31 (12.90%) 4	
Pruritus subjects affected / exposed occurrences (all)	3 / 30 (10.00%) 4	4 / 31 (12.90%) 6	
Dry skin subjects affected / exposed occurrences (all)	3 / 30 (10.00%) 3	2 / 31 (6.45%) 2	
Skin ulcer subjects affected / exposed occurrences (all)	1 / 30 (3.33%) 1	4 / 31 (12.90%) 4	
Blister subjects affected / exposed occurrences (all)	1 / 30 (3.33%) 1	2 / 31 (6.45%) 3	
Skin disorder subjects affected / exposed occurrences (all)	2 / 30 (6.67%) 3	1 / 31 (3.23%) 1	

<p> <b>Dermatitis</b>            subjects affected / exposed            occurrences (all)         </p>	<p>           1 / 30 (3.33%)            1         </p>	<p>           1 / 31 (3.23%)            1         </p>	
<p> <b>Erythema</b>            subjects affected / exposed            occurrences (all)         </p>	<p>           2 / 30 (6.67%)            2         </p>	<p>           0 / 31 (0.00%)            0         </p>	
<p> <b>Dermatitis contact</b>            subjects affected / exposed            occurrences (all)         </p>	<p>           1 / 30 (3.33%)            1         </p>	<p>           0 / 31 (0.00%)            0         </p>	
<p> <b>Hyperhidrosis</b>            subjects affected / exposed            occurrences (all)         </p>	<p>           0 / 30 (0.00%)            0         </p>	<p>           1 / 31 (3.23%)            1         </p>	
<p> <b>Hyperkeratosis</b>            subjects affected / exposed            occurrences (all)         </p>	<p>           1 / 30 (3.33%)            1         </p>	<p>           0 / 31 (0.00%)            0         </p>	
<p> <b>Pruritus allergic</b>            subjects affected / exposed            occurrences (all)         </p>	<p>           1 / 30 (3.33%)            1         </p>	<p>           0 / 31 (0.00%)            0         </p>	
<p> <b>Rash pruritic</b>            subjects affected / exposed            occurrences (all)         </p>	<p>           0 / 30 (0.00%)            0         </p>	<p>           1 / 31 (3.23%)            1         </p>	
<p> <b>Skin maceration</b>            subjects affected / exposed            occurrences (all)         </p>	<p>           1 / 30 (3.33%)            1         </p>	<p>           0 / 31 (0.00%)            0         </p>	
<p> <b>Renal and urinary disorders</b>  <b>Neurogenic bladder</b>            subjects affected / exposed            occurrences (all)         </p>	<p>           5 / 30 (16.67%)            5         </p>	<p>           5 / 31 (16.13%)            5         </p>	
<p> <b>Haematuria</b>            subjects affected / exposed            occurrences (all)         </p>	<p>           2 / 30 (6.67%)            3         </p>	<p>           3 / 31 (9.68%)            3         </p>	
<p> <b>Urinary incontinence</b>            subjects affected / exposed            occurrences (all)         </p>	<p>           1 / 30 (3.33%)            1         </p>	<p>           3 / 31 (9.68%)            3         </p>	
<p> <b>Urinary retention</b> </p>			

subjects affected / exposed	1 / 30 (3.33%)	3 / 31 (9.68%)
occurrences (all)	1	5
Bladder spasm		
subjects affected / exposed	2 / 30 (6.67%)	1 / 31 (3.23%)
occurrences (all)	2	1
Hypertonic bladder		
subjects affected / exposed	1 / 30 (3.33%)	2 / 31 (6.45%)
occurrences (all)	1	3
Renal failure acute		
subjects affected / exposed	0 / 30 (0.00%)	3 / 31 (9.68%)
occurrences (all)	0	3
Polyuria		
subjects affected / exposed	1 / 30 (3.33%)	1 / 31 (3.23%)
occurrences (all)	1	1
Automatic bladder		
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)
occurrences (all)	1	0
Bladder discomfort		
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)
occurrences (all)	1	0
Calculus bladder		
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)
occurrences (all)	0	1
Dysuria		
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)
occurrences (all)	1	0
Glycosuria		
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)
occurrences (all)	1	0
Leukocyturia		
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)
occurrences (all)	2	0
Micturition urgency		
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)
occurrences (all)	1	0
Renal tubular necrosis		

subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	1 / 31 (3.23%) 1	
Urethral haemorrhage subjects affected / exposed occurrences (all)	1 / 30 (3.33%) 1	0 / 31 (0.00%) 0	
Urine abnormality subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	1 / 31 (3.23%) 1	
Endocrine disorders Adrenal insufficiency subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	2 / 31 (6.45%) 2	
Hypothyroidism subjects affected / exposed occurrences (all)	1 / 30 (3.33%) 2	0 / 31 (0.00%) 0	
Musculoskeletal and connective tissue disorders Musculoskeletal pain subjects affected / exposed occurrences (all)	10 / 30 (33.33%) 13	7 / 31 (22.58%) 7	
Muscle spasms subjects affected / exposed occurrences (all)	8 / 30 (26.67%) 8	6 / 31 (19.35%) 7	
Neck pain subjects affected / exposed occurrences (all)	5 / 30 (16.67%) 6	4 / 31 (12.90%) 5	
Pain in extremity subjects affected / exposed occurrences (all)	3 / 30 (10.00%) 3	2 / 31 (6.45%) 3	
Arthralgia subjects affected / exposed occurrences (all)	2 / 30 (6.67%) 3	1 / 31 (3.23%) 2	
Back pain subjects affected / exposed occurrences (all)	1 / 30 (3.33%) 1	2 / 31 (6.45%) 3	
Extraskeletal ossification			

subjects affected / exposed	1 / 30 (3.33%)	2 / 31 (6.45%)
occurrences (all)	1	2
Periarthritis		
subjects affected / exposed	0 / 30 (0.00%)	3 / 31 (9.68%)
occurrences (all)	0	3
Extremity contracture		
subjects affected / exposed	1 / 30 (3.33%)	1 / 31 (3.23%)
occurrences (all)	1	1
Myalgia		
subjects affected / exposed	1 / 30 (3.33%)	1 / 31 (3.23%)
occurrences (all)	1	1
Pain in jaw		
subjects affected / exposed	1 / 30 (3.33%)	1 / 31 (3.23%)
occurrences (all)	1	1
Tendonitis		
subjects affected / exposed	1 / 30 (3.33%)	1 / 31 (3.23%)
occurrences (all)	1	1
Rhabdomyolysis		
subjects affected / exposed	1 / 30 (3.33%)	1 / 31 (3.23%)
occurrences (all)	1	1
Groin pain		
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)
occurrences (all)	1	0
Intervertebral disc protrusion		
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)
occurrences (all)	1	0
Joint contracture		
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)
occurrences (all)	1	0
Joint effusion		
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)
occurrences (all)	1	0
Joint range of motion decreased		
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)
occurrences (all)	1	0
Muscle contracture		

subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)	
occurrences (all)	0	1	
Myofascial pain syndrome			
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)	
occurrences (all)	0	1	
Myositis			
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)	
occurrences (all)	1	0	
Pubic pain			
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)	
occurrences (all)	1	0	
Torticollis			
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)	
occurrences (all)	0	1	
Infections and infestations			
Urinary tract infection			
subjects affected / exposed	20 / 30 (66.67%)	23 / 31 (74.19%)	
occurrences (all)	40	35	
Pneumonia			
subjects affected / exposed	7 / 30 (23.33%)	16 / 31 (51.61%)	
occurrences (all)	8	18	
Respiratory tract infection			
subjects affected / exposed	2 / 30 (6.67%)	3 / 31 (9.68%)	
occurrences (all)	2	3	
Clostridial infection			
subjects affected / exposed	1 / 30 (3.33%)	2 / 31 (6.45%)	
occurrences (all)	2	2	
Upper respiratory tract infection			
subjects affected / exposed	2 / 30 (6.67%)	1 / 31 (3.23%)	
occurrences (all)	2	1	
Candidiasis			
subjects affected / exposed	1 / 30 (3.33%)	1 / 31 (3.23%)	
occurrences (all)	1	1	
Cystitis klebsiella			
subjects affected / exposed	1 / 30 (3.33%)	1 / 31 (3.23%)	
occurrences (all)	1	1	

Nasopharyngitis		
subjects affected / exposed	2 / 30 (6.67%)	0 / 31 (0.00%)
occurrences (all)	2	0
Otitis externa		
subjects affected / exposed	1 / 30 (3.33%)	1 / 31 (3.23%)
occurrences (all)	1	1
Sinusitis		
subjects affected / exposed	1 / 30 (3.33%)	1 / 31 (3.23%)
occurrences (all)	1	1
Staphylococcal infection		
subjects affected / exposed	2 / 30 (6.67%)	0 / 31 (0.00%)
occurrences (all)	2	0
Abdominal infection		
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)
occurrences (all)	0	1
Acarodermatitis		
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)
occurrences (all)	0	1
Acute sinusitis		
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)
occurrences (all)	0	1
Bacterial disease carrier		
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)
occurrences (all)	0	1
Bacteriuria		
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)
occurrences (all)	0	2
Cellulitis		
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)
occurrences (all)	1	0
Clostridium difficile colitis		
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)
occurrences (all)	0	1
Escherichia urinary tract infection		
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)
occurrences (all)	0	1

Fungal infection		
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)
occurrences (all)	1	0
Fungal skin infection		
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)
occurrences (all)	1	0
Gastroenteritis viral		
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)
occurrences (all)	1	0
Herpes dermatitis		
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)
occurrences (all)	1	0
Herpes virus infection		
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)
occurrences (all)	0	1
Herpes zoster		
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)
occurrences (all)	0	1
Infected skin ulcer		
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)
occurrences (all)	0	1
Influenza		
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)
occurrences (all)	0	1
Intraspinal abscess		
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)
occurrences (all)	1	0
Lung infection		
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)
occurrences (all)	0	1
Lung infection pseudomonal		
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)
occurrences (all)	0	1
Nail infection		
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)
occurrences (all)	0	1

Onychomycosis		
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)
occurrences (all)	0	1
Oral candidiasis		
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)
occurrences (all)	1	0
Paronychia		
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)
occurrences (all)	0	1
Pneumonia bacterial		
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)
occurrences (all)	0	1
Pneumonia streptococcal		
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)
occurrences (all)	1	0
Post procedural infection		
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)
occurrences (all)	1	0
Postoperative wound infection		
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)
occurrences (all)	0	1
Purulent discharge		
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)
occurrences (all)	0	1
Rhinitis		
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)
occurrences (all)	0	1
Sepsis		
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)
occurrences (all)	0	1
Tooth abscess		
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)
occurrences (all)	1	0
Tracheitis		
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)
occurrences (all)	1	0

Tracheobronchitis subjects affected / exposed occurrences (all)	1 / 30 (3.33%) 1	0 / 31 (0.00%) 0	
Tracheostomy infection subjects affected / exposed occurrences (all)	1 / 30 (3.33%) 1	0 / 31 (0.00%) 0	
Vulvovaginal candidiasis subjects affected / exposed occurrences (all)	0 / 30 (0.00%) 0	1 / 31 (3.23%) 1	
Vulvovaginal mycotic infection subjects affected / exposed occurrences (all)	1 / 30 (3.33%) 2	0 / 31 (0.00%) 0	
<b>Metabolism and nutrition disorders</b>			
Hypophosphataemia subjects affected / exposed occurrences (all)	5 / 30 (16.67%) 5	5 / 31 (16.13%) 5	
Hypokalaemia subjects affected / exposed occurrences (all)	3 / 30 (10.00%) 5	5 / 31 (16.13%) 8	
Dehydration subjects affected / exposed occurrences (all)	4 / 30 (13.33%) 4	2 / 31 (6.45%) 2	
Hyperglycaemia subjects affected / exposed occurrences (all)	1 / 30 (3.33%) 1	5 / 31 (16.13%) 5	
Hyponatraemia subjects affected / exposed occurrences (all)	4 / 30 (13.33%) 4	2 / 31 (6.45%) 2	
Hypocalcaemia subjects affected / exposed occurrences (all)	3 / 30 (10.00%) 3	1 / 31 (3.23%) 1	
Fluid overload subjects affected / exposed occurrences (all)	1 / 30 (3.33%) 1	2 / 31 (6.45%) 2	
Decreased appetite			

subjects affected / exposed	1 / 30 (3.33%)	1 / 31 (3.23%)
occurrences (all)	1	1
Fluid retention		
subjects affected / exposed	1 / 30 (3.33%)	1 / 31 (3.23%)
occurrences (all)	1	1
Vitamin D deficiency		
subjects affected / exposed	0 / 30 (0.00%)	2 / 31 (6.45%)
occurrences (all)	0	2
Cachexia		
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)
occurrences (all)	0	1
Hypercalcaemia		
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)
occurrences (all)	0	1
Hyperchloraemia		
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)
occurrences (all)	0	1
Hypernatraemia		
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)
occurrences (all)	0	1
Hypoalbuminaemia		
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)
occurrences (all)	1	0
Hypoglycaemia		
subjects affected / exposed	1 / 30 (3.33%)	0 / 31 (0.00%)
occurrences (all)	1	0
Hypomagnesaemia		
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)
occurrences (all)	0	1
Malnutrition		
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)
occurrences (all)	0	1
Sodium retention		
subjects affected / exposed	0 / 30 (0.00%)	1 / 31 (3.23%)
occurrences (all)	0	1



## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
08 August 2011	The overall reason for the amendment was to exclude subjects with renal compromise, hepatic dysfunction, and/or hepatic impairment at screening before the first dose of study drug. - Required that subjects discontinue use of potent CYP3A4/5 inducers for the first 35 days of the study (that is, for the duration of dosing plus 5.5 times the terminal elimination phase half-life of SUN13837). - Added that concomitant administration of CYP3A substrates with a narrow therapeutic index should be avoided during the first 35 days of the study; subjects requiring such therapy should be carefully monitored. - Added that exploratory pharmacokinetic (PK) analysis of 1-benzyl-N-methylpiperidin-4-amine (BMP) (ASB 15490) was conducted. - Added that if blood ethanol concentration (if measured within 72 hours of admission) and/or anatomical length of spinal cord injury was obtained by the hospital as part of patient care, these data, along with date obtained, were to be recorded in the Electronic Case Report Form (eCRF). - Amended the statistical methods section to include multiple imputation methods for handling missing data.
07 November 2012	The overall reason for the amendment was to allow the enrollment of American Spinal Injury Association Impairment Scale grade of B and C (AIS B and C) subjects which allowed for the evaluation of SUN13837 injection in a broader population of acute spinal cord injury subjects. AIS B and C subjects were required to have a Lower Extremity Motor Score (LEMS) of 5 or less points. - Clarified that, at study entry, American Spinal Injury Association Impairment Scale grade of A (AIS A) subjects with a level of injury at cervical level 4 must have at least 1 point of motor activity within the zone of partial preservation inclusive of cervical level 5 to thoracic level 1. - The previous version of the protocol the Spinal Cord Independence Measure, Version III (SCIM III) Self-Care subscale score to confirm the clinical meaningfulness of the primary endpoint. In order to accommodate the inclusion of AIS B and C subjects, the protocol was amended to use the total SCIM III score in this analysis. - Amended the supportive and exploratory efficacy endpoints to accommodate the inclusion of AIS B and C subjects. - Amended the lower age limit to 16 years and the upper age limit to 70 years for AIS B or C subjects. - Allowed sites outside the US and Canada to participate. - Specified that details of the method of imputation were to be included in the Statistical Analysis Plan (SAP).
02 June 2014	The overall reason for the amendment was to drop the requirement that AIS B and C subject must have a LEMS score of 5 or less points. - Amended the primary objective to be based on improvement in measures of overall functional independence based on the final mean total SCIM III. - Amended secondary objectives to include the final mean SCIM III Self-Care and Mobility subscale scores. - Added new secondary objectives related to Total Motor Score (TMS) and AIS grade. - Amended the definition of the Intent to Treat (ITT) population to include SCIM III, rather than International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) assessments. - Added an additional requirement to the ITT population that a subject must have received at least 7 doses of study drug. - Amended the sample size calculation to reflect changes in the primary endpoint. Sample size was changed from 164 subjects to 70 subjects. - Changed the number of sites to 70 with approximately 52 acute centers enrolling subjects.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

## Limitations and caveats

None reported